Frontiers in Clinical Drug Research: Anti-Cancer Agents, Volume 6

Cover
Title
Copyright
End User License Agreement
Contents
Preface
List of Contributors
Immunomodulating Agents in the Treatment of Acute Myeloid Leukemia: A Combinatorial Immunotherapeutic Approach
	Shazia Ali1, Dil Afroze1,*, Javid Rasool2, Bilal Rah4 and Khurshid I. Andrabi3
	INTRODUCTION
		Chemotherapeutic Drugs Used in the Treatment of AML
		AML Relapse
		PI3K/mTOR Pathway
		mTOR Pathway in AML
		TORC1 Targeted Therapy in mTOR
		Novel Therapies in the Treatment of AML
		FLT3 Mutation in AML as a Therapeutic Target
		Targeting Isocitrate Dehydrogenase [IDH] Mutations in AML
		Immunologic Approaches for the Treatment of AML
		The Use of Inhibitors in the Treatment of AML and Concluding Remarks
	FUNDING
	CONSENT FOR PUBLICATION
	CONFLICT OF INTEREST
	ACKNOWLEDGEMENTS
	REFERENCES
Potential Natural Products For Prostate Cancer Management: Prospects For Castration-Resistant Patients
	Thaise G. Araújo1,*, Lara Vecchi1, Danilo S. Costa2, Sara T. S. Mota1, Paula M. A. P. Lima1, Igor M. Campos2, Mariana A. P. Zóia1, Douglas C. Brandão1, Gabriela S. Guimarães1, Matheus A. Ribeiro1 and Ademar A. da Silva Filho2
	INTRODUCTION
	OVERVIEW OF PROSTATE CANCER
		Epidemiology and Etiopathology
		Diagnosis Strategies and Current Treatments
		Biomarkers
		Prostate-Specific Antigen (PSA)
		Pro-PSA
		BPH-related PSA (BPSA)
		Prostate Cancer Antigen 3 (PCA3)
		TMPRSS2: ERG Fusion
		Urokinase-Type Plasminogen Activator (Upa) and its Receptor (Upar)
		Prostate-Specific Membrane Antigen (PSMA)
	ANDROGEN RECEPTOR: FROM CURABLE TO LETHAL DISEASE
		Hallmarks of CRPC
		Signaling Pathways Involved in CRPC
		TGF-β
		Tyrosine Kinase Receptors
		Il-6 Signaling
		Wnt/frizzled/β-Catenin
		NFkB
		Approved Treatments for CRPC
	CHALLENGES AND THE WAY FORWARD TO TREAT CRPC: NATURAL PRODUCTS AS ANTICANCER AGENTS
		Terpenes
			Betulinic Acid
			Glycyrrhetinic Acid
			Ursolic Acid
			Ganoderic Acids
			Lupeol
			Oridonin
			Artemisinin
			Lycopene
			Physachenolide D
		Flavonoids
			Luteolin
			Apigenin
			Quercetin
			Genistein and other Soy Isoflavones
			Silibinin
			Baicalin and Baicalein
		Alkaloids And Anthraquinones
			Sanguinarine
			Emodin
		Other Phenolic And Miscellaneous Compounds
			Resveratrol
			Honokiol
			Curcumin
			Capsaicin and Derivatives
			Wedelolactone
			(-)-Epigallocatechin- 3-Gallate and other Polyphenols Form Green Tea
			Gossypol
			Phenethyl-Isothiocyanate
			Ellagic Acid
			Thymoquinone
			Atraric Acid
			Diindolylmethane
			Sulforaphane
	CONCLUDING REMARKS
	CONSENT FOR PUBLICATION
	CONFLICT OF INTEREST
	ACKNOWLEDGEMENTS
	REFERENCES
Inhibition of Key Protein-Protein Interactions by Small Molecules for Cancer Drug Design
	Aykut Özgür1, Lütfi Tutar2, Mehmet Gümüş3, İrfan Koca4,*, Servet Tunoğlu5, Ezgi Nurdan Yenilmez Tunoğlu5 and Yusuf Tutar6,7,*
	INTRODUCTION
	P53-MDM2 INTERACTION
		Small-Molecule Inhibitors of the p53–MDM2 Interaction
	C-MYC-MAX INTERACTION
		Small-Molecule Inhibitors of the c-Myc-Max Interaction
	BCL-2/BCL-XL INTERACTION
		Small-Molecule Inhibitors of Bcl-2/Bcl-xL Interaction
	HSP90/HSP70 INTERACTION
		Small-Molecule Inhibitors of the Hsp70/Hsp90 Interaction
	Β-CATENIN/TCF4 INTERACTION
		Small-Molecule Inhibitors of the β-Catenin/TCF4 Interaction
	MENIN/MLL INTERACTION
		Small-Molecule Inhibitors of the Menin-MLL Interaction
	CONCLUSION
	CONSENT FOR PUBLICATION
	CONFLICT OF INTEREST
	ACKNOWLEDGEMENTS
	REFERENCES
Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) for Advanced Hepatocellular Carcinoma
	Kei Moriya*, Tadashi Namisaki and Hitoshi Yoshiji
	INTRODUCTION
		The Best Choice for Managing Advanced Hepatocellular Carcinoma
		What is Hepatic Arterial Infusion Chemotherapy (HAIC)?
		One-shot HAIC and its Clinical Outcome for HCC
		Reservoir Systems for Chemotherapy
			Setting of Reservoir Systems
			Management of Reservoir System and its Related Adverse Events
			Reservoir HAIC Regimen and Clinical Outcome for HCC
		Evaluation of the Curative Effect of HAIC and its Prognostic Value
		Which Type of HAIC Would be Useful?
		When to use HAIC Combination Therapy with Molecularly Targeted Drugs or Surgical Resection for Advanced HCC with Major Ductal Invasions
		A New Derivation of Modified HAIC
		Which is Better, HAIC, or Molecularly Targeted Agents?
	SUMMARY
	CONSENT FOR PUBLICATION
	CONFLICT OF INTEREST
	ACKNOWLEDGEMENTS
	REFERENCES
Targeting Cancer Stem Cells: Implications in Health and Disease
	Roshia Ali1,2,*, Hilal Ahmad Mir2, Rabia Hamid3, Sahar Saleem Bhat4 and Firdous A. Khanday2
	INTRODUCTION
	STEM CELLS
	CANCER STEM CELLS
	CSC NICHE - CROSS TALK BETWEEN CSC AND TUMOR MICROENVIRONMENT
	CSC BIOMARKERS
		CD133
		CD24
		CD44
		ALDH
	CSCS IN TUMORIGENIC PROCESS
	THERAPEUTIC APPROACHES TO TARGET CSCS - PRECLINICAL AND CLINICAL ROUTE
		Targeting Cellular Surface CSC Markers
		Immunotherapeutic Approaches to Targeting CSCs
		Targeting CSC Metabolism
		Targeting Key Signal Pathways
	CONCLUSION AND PERSPECTIVES
	AUTHOR CONTRIBUTIONS
	CONSENT FOR PUBLICATION
	CONFLICT OF INTEREST
	ACKNOWLEDGEMENTS
	REFERENCES
Subject Index
Back Cover